logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Regenacy Pharmaceuticals Raises $30 Million in Series A Financing

Mar 25, 2020•over 5 years ago

Amount Raised

$30 Million

Round Type

series a

Waltham

Description

Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing. The financing was co-led by Cobro Ventures and Taiwania Capital Management Corporation, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA VENTURE HOLDINGS LIMITED, and other undisclosed private investors.

Company Information

Company

Regenacy

Location

Waltham, Massachusetts, United States

About

Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders. www.regenacy.com

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech